A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis
- PMID: 36357514
- PMCID: PMC9649731
- DOI: 10.1038/s41598-022-23180-2
A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis
Abstract
Anti-cyclic citrullinated peptide antibody testing is used to diagnose rheumatoid arthritis and associated with interstitial lung disease in RA. Herein, we investigate the relationship between anti-CCP antibody and ILD in SSc. We performed a retrospective analysis at a tertiary medical center between 2005 and 2019. Patients with SSc, systemic lupus erythematosus, and polymyositis/dermatomyositis (PM/DM) were evaluated for anti-CCP antibody and ILD. Additionally, medical records of SSc patients with ILD were reviewed. SSc patients had the highest anti-CCP antibody positivity rate compared to those with SLE and PM/DM. The incidence of ILD was higher in SSc patients with anti-CCP antibody than in those without. The usual interstitial pneumonia (UIP) incidence was higher in the anti-CCP antibody-positive group than in the anti-CCP antibody-negative group. The DLCO was lower in the anti-CCP antibody-positive group than in the anti-CCP antibody-negative group. On multivariable analysis, factors associated with SSc-ILD were anti-CCP antibody or rheumatoid factor (β coefficient, 2.652 [95% CI 1.472 to 4.776]) and anti-Scl70 antibody (β coefficient, 4.011 [95% CI 2.142 to 7.508]). Anti-CCP antibody may be associated with a higher incidence of ILD in SSc. SSc patients with anti-CCP antibody may have more UIP pattern and lower DLCO.Trial Registration Retrospectively registered.
© 2022. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures

Similar articles
-
Identification and management of interstitial lung disease associated with systemic sclerosis (SSc-ILD), rheumatoid arthritis (RA-ILD), and polymyositis/dermatomyositis (PM/DM-ILD): development of expert consensus-based clinical algorithms.Expert Rev Respir Med. 2024 Jun;18(6):447-456. doi: 10.1080/17476348.2024.2374910. Epub 2024 Jul 15. Expert Rev Respir Med. 2024. PMID: 38943279
-
Anti-cyclic citrullinated peptide antibody in systemic sclerosis.Clin Exp Rheumatol. 2008 Jul-Aug;26(4):542-7. Clin Exp Rheumatol. 2008. PMID: 18799082
-
Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.Front Immunol. 2023 Jul 19;14:1197458. doi: 10.3389/fimmu.2023.1197458. eCollection 2023. Front Immunol. 2023. PMID: 37539050 Free PMC article.
-
Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody.BMJ Open. 2021 Mar 31;11(3):e040465. doi: 10.1136/bmjopen-2020-040465. BMJ Open. 2021. PMID: 33789847 Free PMC article.
-
Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?Int J Mol Sci. 2023 May 28;24(11):9388. doi: 10.3390/ijms24119388. Int J Mol Sci. 2023. PMID: 37298342 Free PMC article. Review.
Cited by
-
Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to 2022 ACR/EULAR criteria.Korean J Intern Med. 2024 May;39(3):524-536. doi: 10.3904/kjim.2023.189. Epub 2024 Jan 29. Korean J Intern Med. 2024. PMID: 38282414 Free PMC article.
-
Autoantibodies as putative biomarkers and triggers of cell dysfunctions in systemic sclerosis.Curr Opin Rheumatol. 2025 Jan 1;37(1):51-63. doi: 10.1097/BOR.0000000000001035. Epub 2024 Aug 2. Curr Opin Rheumatol. 2025. PMID: 39046085 Free PMC article. Review.
-
Treating connective tissue disease-associated interstitial lung disease - think outside the box: a perspective.Eur Respir Rev. 2025 Jul 23;34(177):250046. doi: 10.1183/16000617.0046-2025. Print 2025 Jul. Eur Respir Rev. 2025. PMID: 40701643 Free PMC article. Review.
-
The interplay between rheumatic diseases and pulmonary health.Rheumatol Int. 2024 Jul;44(7):1179-1184. doi: 10.1007/s00296-024-05565-w. Epub 2024 Mar 20. Rheumatol Int. 2024. PMID: 38509351 Review.
References
-
- van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Jr, Carreira PE, et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum Dis. 2013;72(11):1747–1755. - PubMed
-
- Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, Han J. Interstitial lung diseases associated with collagen vascular diseases: Radiologic and histopathologic findings. Radiographics. 2002;22(suppl_1):S151–S165. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical